{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00025965", "CSN": null, "TRF": "ORD_1537948_01", "MRN": "48308312", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1258216", "clinicalId": "1259586", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1537948_01", "SampleName": "US1470814.01", "Version": "0", "Sample": {"FM_Id": "ORD_1537948_01", "SampleId": "US1470814.01", "BlockId": "nan", "TRFNumber": "ORD_1537948_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2023_01_05", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "14", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10014", "MRN": "48308312", "FullName": "\u8521\u9e97\u8389", "FirstName": "Li_Li", "LastName": "Tsai", "SubmittedDiagnosis": "Unknown primary sarcoma (NOS)", "Gender": "Female", "DOB": "1965_04_26", "OrderingMD": "\u984f\u53a5\u5168", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2023_01_03", "ReceivedDate": "2023-01-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "Q2628H"}, {"geneName": "ARID1A", "isVUS": "true", "variantName": "V1753E"}, {"geneName": "ATRX", "isVUS": "true", "variantName": "T1582A"}, {"geneName": "AXL", "isVUS": "true", "variantName": "S685F"}, {"geneName": "CBL", "isVUS": "true", "variantName": "T402P"}, {"geneName": "CDK12", "isVUS": "true", "variantName": "L926F"}, {"geneName": "CSF3R", "isVUS": "true", "variantName": "Q245K"}, {"geneName": "CTCF", "isVUS": "true", "variantName": "N332Y"}, {"geneName": "CUL4A", "isVUS": "true", "variantName": "G35R"}, {"geneName": "ESR1", "isVUS": "true", "variantName": "M251I"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "G584V"}, {"geneName": "JAK3", "isVUS": "true", "variantName": "V464I"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "L1426S"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ATRX", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 5787_20_5796>TTAAACAAAC", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "6.42", "isEquivocal": "false", "name": "splice site 5787_20_5796>TTAAACAAAC"}}, "Interpretation": "ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and W\u00f6hrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Published data investigating the prognostic implications of bTMB levels in sarcoma are limited (PubMed, Jul 2022). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2022). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CBL", "Include": "true", "Alterations": {"Alteration": {"Name": "R420Q", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.54", "isEquivocal": "false", "name": "R420Q"}}, "Interpretation": "CBL encodes an E3 ubiquitin protein ligase that is involved in cell signaling and ubiquitination, targeting proteins such as EGFR, FGFR1, FGFR2, PDGFR_alpha, PDGFR_beta, FLT3, and SRC for degradation by the proteasome (Bacher et al., 2010; 20195608, Miyake et al., 1999; 10347229, Polzer et al., 2012; 23127761, Levkowitz et al., 1998; 9851973, Bunda et al., 2013; 23400592). CBL alterations that result in loss or disruption of the tyrosine kinase binding domain, RING finger domain, and/or tail domain, as observed here, are predicted to be inactivating and to promote tumorigenesis (Andonoiou et al., 1994; 7925293, Aranaz et al., 2012; 22315494, Fernandes et al., 2010; 20622007, Grand et al., 2009; 19387008, Javadi et al., 2013; 23696637, Kassenbrock et al., 2004; 15117950, Levkowitz et al., 1999; 10635327, Loh et al., 2009; 19571318, Martinelli et al., 2010; 20619386, Saito et al., 2012; 22591685, Sanada et al., 2009; 19620960, Score et al., 2012; 22053108, Shiba et al., 2011; 21494262, Standaert et al., 2004; 15581361, Tan et al., 2010; 20126411, Thien et al., 2001; 11239464, Visser and Lill, 2005; 16246327, Li et al., 2016; 26676746). In the Sarcoma MSKCC dataset, CBL mutations were not reported in any of the 207 samples (cBio_Barretina et al., 2010; 20601955). Published data investigating the prognostic implications of CBL alterations in sarcoma are limited (PubMed, Apr 2022). CBL inactivation may lead to the hyperactivation of various receptor tyrosine kinases (RTKs), including MET (Mancini et al., 2002; 11847211), PDGFRA (Miyake et al., 1998; 9653117), KIT (Masson et al., 2006; 16780420), VEGFR2 (Singh et al., 2007; 17372230), and the TAM (TYRO3, AXL, MER) RTKs (Paolino et al., 2014; 24553136). These RTKs are targets of the multikinase inhibitor sitravatinib (Patwardhan et al., 2016; 26675259), which has shown activity in CBL_mutated advanced solid tumors (Bazhenova et al., 2018; ESMO Abstract 408O). Among 8 patients with CBL inactivating alterations in a Phase 1b trial, sitravatinib produced 2 PRs (25% ORR), with 1 NSCLC and 1 melanoma responding for over 4 months, and 4 SD outcomes, with 3 prolonged SDs seen in a patient with NSCLC, a patient with esophageal cancer, and a patient with a pancreatic neuroendocrine tumor (Bazhenova et al., 2018; ESMO Abstract 408O). CBL has been shown to downregulate EGFR (Shtiegman et al., 2007; 17486068, Padr\u00f3n et al., 2007; 17699773, Hosaka et al., 2007; 17695511, Han et al., 2006; 16969069, Yang et al., 2006; 16849543) and FLT3 (Sargin et al., 2007; 17446348, Oshikawa et al., 2011; 21768087, Reindl et al., 2009; 19276253). Preclinical models of myeloid malignancies have demonstrated that CBL inactivation confers sensitivity to the FLT3_targeting therapies sunitinib (Sargin et al., 2007; 17446348), midostaurin (Reindl et al., 2009; 19276253), and quizartinib (Taylor et al., 2012; 22990016), as well as to dasatinib (Makishima et al., 2012; 22246246), although clinical evidence for this approach in solid tumors is lacking. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "JAK2", "Include": "true", "Alterations": {"Alteration": {"Name": "V617F", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.14", "isEquivocal": "false", "name": "V617F"}}, "Interpretation": "JAK2 encodes Janus kinase 2, a tyrosine kinase that regulates signals triggered by cytokines and growth factors (Jatiani et al., 2010; 21442038). JAK2 is often mutated in hematopoietic and lymphoid cancers. The JAK2 alteration observed here has been characterized as activating and is predicted to be oncogenic (Shan et al., 2014; 2491854, Zhao et al., 2009; 19638629, Walz et al., 2006; 16632470, Kralovics et al., 2005; 15858187, Etheridge et al., 2014; 24381227, Marty et al., 2014; 24398328, Jatiani et al., 2010; 21442038, Ma et al., 2009; 19074595, Wu et al., 2013; 23452118, Mullighan et al., 2009; 19470474, Yoda et al., 2010; 20018760, Mercher et al., 2006; 16804112, Zou et al., 2011; 21362419, Funakoshi_Tago et al., 2009; 19289461, Zhao et al., 2009; 19638629, Grisouard et al., 2016; 27288519, Scott et al., 2007; 17267906). Limited clinical data suggest that JAK2 V617F mutations detected in solid tumors may originate from infiltrating hematopoietic cells and not the tumor itself (Riedlinger et al., 2019; 30605212). JAK2 mutation was not detected in any of the 306 soft tissue sarcoma cases analyzed in COSMIC (Aug 2022)(Tate et al., 2019; 30371878). The frequency of JAK2 rearrangements in sarcomas has not been evaluated (cBioPortal, PubMed, Aug 2022)(cBio_Barretina et al., 2010; 20601955, Cancer Genome Atlas Research Network., 2017; 29100075). Published data investigating the prognostic implications of JAK2 alteration in sarcoma are limited (PubMed, Aug 2022). While JAK2 inhibitors have shown clinical benefit in hematological malignancies, clinical utility in solid tumors has not been demonstrated. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). However, reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In these smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). In one study, MSI was reported to occur more frequently in high_grade soft tissue sarcomas compared with lower grade (Ruci\u0144ska et al., 2005; 15668629). However, published data investigating the prognostic implications of MSI in sarcoma are limited (PubMed, Jan 2023). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "K722fs*1", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "10.28", "isEquivocal": "false", "name": "K722fs*1"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 mutation and deletion have been reported in 4.44% and 6.97% of sarcomas, respectively (Nacev et al., 2022; 35705560), but are frequently reported in leiomyosarcoma (Elvin et al., 2017; 28283584, Williams et al., 2020; 33015533). One study reported homozygous deletion of RB1 in 2/36 (5.5%) of undifferentiated pleomorphic sarcomas (previously called malignant fibrous histiocytoma), but loss of RB1 expression in 30/35 (86%), suggesting that loss of RB1 plays a pivotal role in the pathogenesis of this group of soft tissue sarcomas (Chibon et al., 2000; 11103795). In one study, decreased Rb protein expression was associated with improved overall survival in patients with soft tissue sarcoma (Shim et al, 2010; 20948919). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "23916100", "FullCitation": "Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100", "Include": "true"}, {"number": "1", "ReferenceId": "23249563", "FullCitation": "Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563", "Include": "true"}, {"number": "2", "ReferenceId": "22829774", "FullCitation": "Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774", "Include": "true"}, {"number": "3", "ReferenceId": "23185534", "FullCitation": "Bower K, et al. PLoS ONE (2012) pmid: 23185534", "Include": "true"}, {"number": "4", "ReferenceId": "21719641", "FullCitation": "Heaphy CM, et al. Science (2011) pmid: 21719641", "Include": "true"}, {"number": "5", "ReferenceId": "25229770", "FullCitation": "Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770", "Include": "true"}, {"number": "6", "ReferenceId": "17296936", "FullCitation": "Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936", "Include": "true"}, {"number": "7", "ReferenceId": "14729260", "FullCitation": "Garrick D, et al. Gene (2004) pmid: 14729260", "Include": "true"}, {"number": "8", "ReferenceId": "21666677", "FullCitation": "Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677", "Include": "true"}, {"number": "9", "ReferenceId": "25593184", "FullCitation": "Flynn RL, et al. Science (2015) pmid: 25593184", "Include": "true"}, {"number": "10", "ReferenceId": "7697714", "FullCitation": "Gibbons RJ, et al. Cell (1995) pmid: 7697714", "Include": "true"}, {"number": "11", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "12", "ReferenceId": "25608029", "FullCitation": "Fishbein L, et al. Nat Commun (2015) pmid: 25608029", "Include": "true"}, {"number": "13", "ReferenceId": "22416102", "FullCitation": "Cheung NK, et al. JAMA (2012) pmid: 22416102", "Include": "true"}, {"number": "14", "ReferenceId": "22367537", "FullCitation": "Molenaar JJ, et al. Nature (2012) pmid: 22367537", "Include": "true"}, {"number": "15", "ReferenceId": "23334666", "FullCitation": "Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666", "Include": "true"}, {"number": "16", "ReferenceId": "23702928", "FullCitation": "Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928", "Include": "true"}, {"number": "17", "ReferenceId": "24148618", "FullCitation": "Marinoni I, et al. Gastroenterology (2014) pmid: 24148618", "Include": "true"}, {"number": "18", "ReferenceId": "24468746", "FullCitation": "Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746", "Include": "true"}, {"number": "19", "ReferenceId": "26936505", "FullCitation": "Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505", "Include": "true"}, {"number": "20", "ReferenceId": "23104868", "FullCitation": "Kannan K, et al. Oncotarget (2012) pmid: 23104868", "Include": "true"}, {"number": "21", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "22", "ReferenceId": "25427834", "FullCitation": "Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834", "Include": "true"}, {"number": "23", "ReferenceId": "25143301", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301", "Include": "true"}, {"number": "24", "ReferenceId": "31551363", "FullCitation": "Liang J, et al. Cancer Res (2020) pmid: 31551363", "Include": "true"}, {"number": "25", "ReferenceId": "34118569", "FullCitation": "Garbarino J, et al. Transl Oncol (2021) pmid: 34118569", "Include": "true"}, {"number": "26", "ReferenceId": "32846370", "FullCitation": "George SL, et al. EBioMedicine (2020) pmid: 32846370", "Include": "true"}, {"number": "27", "ReferenceId": "21442038", "FullCitation": "Jatiani SS, et al. Genes Cancer (2010) pmid: 21442038", "Include": "true"}, {"number": "28", "ReferenceId": "2491854", "FullCitation": "Bicsak TA, et al. J. Biol. Chem. (1989) pmid: 2491854", "Include": "true"}, {"number": "29", "ReferenceId": "19638629", "FullCitation": "Zhao L, et al. J. Biol. Chem. (2009) pmid: 19638629", "Include": "true"}, {"number": "30", "ReferenceId": "16632470", "FullCitation": "Walz C, et al. J. Biol. Chem. (2006) pmid: 16632470", "Include": "true"}, {"number": "31", "ReferenceId": "15858187", "FullCitation": "Kralovics R, et al. N. Engl. J. Med. (2005) pmid: 15858187", "Include": "true"}, {"number": "32", "ReferenceId": "24381227", "FullCitation": "Etheridge SL, et al. Blood (2014) pmid: 24381227", "Include": "true"}, {"number": "33", "ReferenceId": "24398328", "FullCitation": "Marty C, et al. Blood (2014) pmid: 24398328", "Include": "true"}, {"number": "34", "ReferenceId": "19074595", "FullCitation": "Ma W, et al. J Mol Diagn (2009) pmid: 19074595", "Include": "true"}, {"number": "35", "ReferenceId": "23452118", "FullCitation": "Wu QY, et al. Leuk. Lymphoma (2013) pmid: 23452118", "Include": "true"}, {"number": "36", "ReferenceId": "19470474", "FullCitation": "Mullighan CG, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19470474", "Include": "true"}, {"number": "37", "ReferenceId": "20018760", "FullCitation": "Yoda A, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018760", "Include": "true"}, {"number": "38", "ReferenceId": "16804112", "FullCitation": "Mercher T, et al. Blood (2006) pmid: 16804112", "Include": "true"}, {"number": "39", "ReferenceId": "21362419", "FullCitation": "Zou H, et al. FEBS Lett. (2011) pmid: 21362419", "Include": "true"}, {"number": "40", "ReferenceId": "19289461", "FullCitation": "Funakoshi_Tago M, et al. J. Biol. Chem. (2009) pmid: 19289461", "Include": "true"}, {"number": "41", "ReferenceId": "27288519", "FullCitation": "Grisouard J, et al. Blood (2016) pmid: 27288519", "Include": "true"}, {"number": "42", "ReferenceId": "17267906", "FullCitation": "Scott LM, et al. N. Engl. J. Med. (2007) pmid: 17267906", "Include": "true"}, {"number": "43", "ReferenceId": "30605212", "FullCitation": "Riedlinger G, et al. JAMA Oncol (2019) pmid: 30605212", "Include": "true"}, {"number": "44", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "45", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "46", "ReferenceId": "29100075", "FullCitation": "Cancer Genome Atlas Research Network. Electronic address: elizabeth.demiccosinaihealthsystem.ca, et al. Cell (2017) pmid: 29100075", "Include": "true"}, {"number": "47", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "48", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "49", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "50", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "51", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "52", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "53", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "54", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "55", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "56", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "57", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "58", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "59", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "60", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "61", "ReferenceId": "8162069", "FullCitation": "Wooster R, et al. Nat. Genet. (1994) pmid: 8162069", "Include": "true"}, {"number": "62", "ReferenceId": "15643505", "FullCitation": "Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505", "Include": "true"}, {"number": "63", "ReferenceId": "14562278", "FullCitation": "Saito T, et al. Hum. Pathol. (2003) pmid: 14562278", "Include": "true"}, {"number": "64", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "65", "ReferenceId": "16619000", "FullCitation": "Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000", "Include": "true"}, {"number": "66", "ReferenceId": "9689926", "FullCitation": "Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926", "Include": "true"}, {"number": "67", "ReferenceId": "15668629", "FullCitation": "Ruci\u0144ska M, et al. Med. Sci. Monit. (2005) pmid: 15668629", "Include": "true"}, {"number": "68", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "69", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "70", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "71", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "72", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "73", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "74", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "75", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "76", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "77", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "78", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "79", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "80", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "81", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "82", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "83", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "84", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "85", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "86", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "87", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "88", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "89", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "90", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "91", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "92", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "93", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "94", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "95", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "96", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "97", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "98", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "99", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "100", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "101", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "102", "ReferenceId": "35705560", "FullCitation": "Nacev BA, et al. Nat Commun (2022) pmid: 35705560", "Include": "true"}, {"number": "103", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "104", "ReferenceId": "33015533", "FullCitation": "Williams EA, et al. JCO Precis Oncol (2020) pmid: 33015533", "Include": "true"}, {"number": "105", "ReferenceId": "11103795", "FullCitation": "Chibon F, et al. Cancer Res. (2000) pmid: 11103795", "Include": "true"}, {"number": "106", "ReferenceId": "20948919", "FullCitation": "Shim BY, et al. Cancer Res Treat (2010) pmid: 20948919", "Include": "true"}, {"number": "107", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "108", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "109", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "110", "ReferenceId": "34741392", "FullCitation": "Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392", "Include": "true"}, {"number": "111", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "112", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "113", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "114", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "115", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "116", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "117", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "118", "ReferenceId": "20195608", "FullCitation": "Bacher U, et al. Ann. Hematol. (2010) pmid: 20195608", "Include": "true"}, {"number": "119", "ReferenceId": "10347229", "FullCitation": "Miyake S, et al. J. Biol. Chem. (1999) pmid: 10347229", "Include": "true"}, {"number": "120", "ReferenceId": "23127761", "FullCitation": "Polzer H, et al. Exp. Hematol. (2013) pmid: 23127761", "Include": "true"}, {"number": "121", "ReferenceId": "9851973", "FullCitation": "Levkowitz G, et al. Genes Dev. (1998) pmid: 9851973", "Include": "true"}, {"number": "122", "ReferenceId": "23400592", "FullCitation": "Bunda S, et al. Cancer Res. (2013) pmid: 23400592", "Include": "true"}, {"number": "123", "ReferenceId": "7925293", "FullCitation": "Andoniou CE, et al. EMBO J. (1994) pmid: 7925293", "Include": "true"}, {"number": "124", "ReferenceId": "22315494", "FullCitation": "Aranaz P, et al. Haematologica (2012) pmid: 22315494", "Include": "true"}, {"number": "125", "ReferenceId": "20622007", "FullCitation": "Fernandes MS, et al. J. Biol. Chem. (2010) pmid: 20622007", "Include": "true"}, {"number": "126", "ReferenceId": "19387008", "FullCitation": "Grand FH, et al. Blood (2009) pmid: 19387008", "Include": "true"}, {"number": "127", "ReferenceId": "23696637", "FullCitation": "Javadi M, et al. J. Biol. Chem. (2013) pmid: 23696637", "Include": "true"}, {"number": "128", "ReferenceId": "15117950", "FullCitation": "Kassenbrock CK, et al. J. Biol. Chem. (2004) pmid: 15117950", "Include": "true"}, {"number": "129", "ReferenceId": "10635327", "FullCitation": "Levkowitz G, et al. Mol. Cell (1999) pmid: 10635327", "Include": "true"}, {"number": "130", "ReferenceId": "19571318", "FullCitation": "Loh ML, et al. Blood (2009) pmid: 19571318", "Include": "true"}, {"number": "131", "ReferenceId": "20619386", "FullCitation": "Martinelli S, et al. Am. J. Hum. Genet. (2010) pmid: 20619386", "Include": "true"}, {"number": "132", "ReferenceId": "22591685", "FullCitation": "Saito Y, et al. Leuk. Res. (2012) pmid: 22591685", "Include": "true"}, {"number": "133", "ReferenceId": "19620960", "FullCitation": "Sanada M, et al. Nature (2009) pmid: 19620960", "Include": "true"}, {"number": "134", "ReferenceId": "22053108", "FullCitation": "Score J, et al. Blood (2012) pmid: 22053108", "Include": "true"}, {"number": "135", "ReferenceId": "21494262", "FullCitation": "Shiba N, et al. Leukemia (2011) pmid: 21494262", "Include": "true"}, {"number": "136", "ReferenceId": "15581361", "FullCitation": "Standaert ML, et al. Biochemistry (2004) pmid: 15581361", "Include": "true"}, {"number": "137", "ReferenceId": "20126411", "FullCitation": "Tan YH, et al. PLoS ONE (2010) pmid: 20126411", "Include": "true"}, {"number": "138", "ReferenceId": "11239464", "FullCitation": "Thien CB, et al. Mol. Cell (2001) pmid: 11239464", "Include": "true"}, {"number": "139", "ReferenceId": "16246327", "FullCitation": "Visser GD, et al. Exp. Cell Res. (2005) pmid: 16246327", "Include": "true"}, {"number": "140", "ReferenceId": "26676746", "FullCitation": "Li M, et al. Cancer Res. (2016) pmid: 26676746", "Include": "true"}, {"number": "141", "ReferenceId": "11847211", "FullCitation": "Mancini A, et al. J. Biol. Chem. (2002) pmid: 11847211", "Include": "true"}, {"number": "142", "ReferenceId": "9653117", "FullCitation": "Miyake S, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9653117", "Include": "true"}, {"number": "143", "ReferenceId": "16780420", "FullCitation": "Masson K, et al. Biochem. J. (2006) pmid: 16780420", "Include": "true"}, {"number": "144", "ReferenceId": "17372230", "FullCitation": "Singh AJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17372230", "Include": "true"}, {"number": "145", "ReferenceId": "24553136", "FullCitation": "Paolino M, et al. Nature (2014) pmid: 24553136", "Include": "true"}, {"number": "146", "ReferenceId": "26675259", "FullCitation": "Patwardhan PP, et al. Oncotarget (2016) pmid: 26675259", "Include": "true"}, {"number": "147", "ReferenceId": "17486068", "FullCitation": "Shtiegman K, et al. Oncogene (2007) pmid: 17486068", "Include": "true"}, {"number": "148", "ReferenceId": "17699773", "FullCitation": "Padr\u00f3n D, et al. Cancer Res. (2007) pmid: 17699773", "Include": "true"}, {"number": "149", "ReferenceId": "17695511", "FullCitation": "Hosaka T, et al. Anticancer Res. () pmid: 17695511", "Include": "true"}, {"number": "150", "ReferenceId": "16969069", "FullCitation": "Han W, et al. Cancer Biol. Ther. (2006) pmid: 16969069", "Include": "true"}, {"number": "151", "ReferenceId": "16849543", "FullCitation": "Yang S, et al. Cancer Res. (2006) pmid: 16849543", "Include": "true"}, {"number": "152", "ReferenceId": "17446348", "FullCitation": "Sargin B, et al. Blood (2007) pmid: 17446348", "Include": "true"}, {"number": "153", "ReferenceId": "21768087", "FullCitation": "Oshikawa G, et al. J. Biol. Chem. (2011) pmid: 21768087", "Include": "true"}, {"number": "154", "ReferenceId": "19276253", "FullCitation": "Reindl C, et al. Clin. Cancer Res. (2009) pmid: 19276253", "Include": "true"}, {"number": "155", "ReferenceId": "22990016", "FullCitation": "Taylor SJ, et al. Blood (2012) pmid: 22990016", "Include": "true"}, {"number": "156", "ReferenceId": "22246246", "FullCitation": "Makishima H, et al. Leukemia (2012) pmid: 22246246", "Include": "true"}, {"number": "157", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "158", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "159", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "160", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "161", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "162", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "163", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "164", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "165", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "166", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "167", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "168", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "169", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "170", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "171", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "172", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "173", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "174", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "175", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "176", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_12 21:57:12", "OpName": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "14%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary sarcoma (NOS)", "flowcell_analysis": "2000026859", "gender": "female", "pathology_diagnosis": "Sarcoma", "pipeline_version": "v3.18.0", "purity_assessment": "31.5", "specimen": "ORD_1537948_01*US1470814.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1537948_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1470814.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0642", "cds_effect": "5787_20_5796>TTAAACAAAC", "depth": "1309", "equivocal": "false", "functional_effect": "splice", "gene": "ATRX", "percent_reads": "6.42", "position": "chrX:76855040", "protein_effect": "splice site 5787_20_5796>TTAAACAAAC", "status": "likely", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.2987", "cds_effect": "103G>C", "depth": "154", "equivocal": "false", "functional_effect": "missense", "gene": "CUL4A", "percent_reads": "29.87", "position": "chr13:113864044", "protein_effect": "G35R", "status": "unknown", "strand": "+", "transcript": "NM_001008895", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.1028", "cds_effect": "2164_2173delAAAATCATTG", "depth": "5117", "equivocal": "false", "functional_effect": "frameshift", "gene": "RB1", "percent_reads": "10.28", "position": "chr13:49037923", "protein_effect": "K722fs*1", "status": "likely", "strand": "+", "transcript": "NM_000321", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.1266", "cds_effect": "4744A>G", "depth": "1674", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "12.66", "position": "chrX:76890150", "protein_effect": "T1582A", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.5004", "cds_effect": "733C>A", "depth": "1251", "equivocal": "false", "functional_effect": "missense", "gene": "CSF3R", "percent_reads": "50.04", "position": "chr1:36938228", "protein_effect": "Q245K", "status": "unknown", "strand": "_", "transcript": "NM_156039", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0068", "cds_effect": "1204A>C", "depth": "1326", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "0.68", "position": "chr11:119148984", "protein_effect": "T402P", "status": "unknown", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.4379", "cds_effect": "1390G>A", "depth": "1361", "equivocal": "false", "functional_effect": "missense", "gene": "JAK3", "percent_reads": "43.79", "position": "chr19:17950337", "protein_effect": "V464I", "status": "unknown", "strand": "_", "transcript": "NM_000215", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0014", "cds_effect": "1849G>T", "depth": "5521", "equivocal": "false", "functional_effect": "missense", "gene": "JAK2", "percent_reads": "0.14", "position": "chr9:5073770", "protein_effect": "V617F", "status": "known", "strand": "+", "transcript": "NM_004972", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0013", "cds_effect": "2776C>T", "depth": "3723", "equivocal": "false", "functional_effect": "missense", "gene": "CDK12", "percent_reads": "0.13", "position": "chr17:37671991", "protein_effect": "L926F", "status": "unknown", "strand": "+", "transcript": "NM_016507", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0013", "cds_effect": "1751G>T", "depth": "6039", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "0.13", "position": "chr20:57430071", "protein_effect": "G584V", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0032", "cds_effect": "5258T>A", "depth": "1254", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "0.32", "position": "chr1:27105647", "protein_effect": "V1753E", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.007", "cds_effect": "753G>T", "depth": "1426", "equivocal": "false", "functional_effect": "missense", "gene": "ESR1", "percent_reads": "0.7", "position": "chr6:152201899", "protein_effect": "M251I", "status": "unknown", "strand": "+", "transcript": "NM_000125", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0634", "cds_effect": "2054C>T", "depth": "1514", "equivocal": "false", "functional_effect": "missense", "gene": "AXL", "percent_reads": "6.34", "position": "chr19:41762401", "protein_effect": "S685F", "status": "unknown", "strand": "+", "transcript": "NM_001699", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0017", "cds_effect": "7884G>T", "depth": "6611", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "0.17", "position": "chr5:112179175", "protein_effect": "Q2628H", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0054", "cds_effect": "1259G>A", "depth": "1487", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "0.54", "position": "chr11:119149251", "protein_effect": "R420Q", "status": "known", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.4805", "cds_effect": "4277T>C", "depth": "1667", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "48.05", "position": "chr1:16257012", "protein_effect": "L1426S", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"allele_fraction": "0.0051", "cds_effect": "994A>T", "depth": "1385", "equivocal": "false", "functional_effect": "missense", "gene": "CTCF", "percent_reads": "0.51", "position": "chr16:67670733", "protein_effect": "N332Y", "status": "unknown", "strand": "+", "transcript": "NM_001191022", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.32", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "27", "status": "unknown", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}, {"organism": "HHV_4", "reads_per_million": "19", "status": "unknown", "dna_evidence": {"sample": "SQ_US1470814.01_1"}}]}}}}}